Phase III Study Data With Vandetanib In Patients With Advanced

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

ZODIAC is a randomised, double-blind, placebo- controlled Phase III study evaluating the combination of vandetanib 100mg with docetaxel versus docetaxel alone. The study enrolled 1391 patients previously treated with one prior anti- cancer therapy for advanced NSCLC.